Clinical trials: Psychosis NOS
Psychosis Prodrome
Ziprasidone in the Psychosis Prodrome
This study aims to determine whether ziprasidone is superior to placebo over 24 weeks for patients with the psychosis prodrome.
- Trial name
- ZIP (NCT00635700)
- Testing
- ziprasidone
- Where
- 11 sites in United States, Canada
- Volunteers
- 51 people
- Sponsor
- Yale University
Psychosis, Bipolar Disorder
Young People and Illness Management and Recovery (IMR)
The study is a combined clinical patient outcome study and a health-services research sub-study. Illness management and recovery (IMR) constitutes an evidence-based practice with 11 modules focusing on personal recovery developed…
- Conditions
- Psychosis, Bipolar Disorder, Other Diagnoses and Conditions
- Trial name
- NCT04778085
- Testing
- Illness management and recovery, Semi-structured interviews
- Where
- Norway
- Volunteers
- 10 people
- Sponsor
- University Hospital, Akershus
Alzheimer's Disease, Psychosis
Treatment of Psychosis and Agitation in Alzheimer's Disease
Clinically, many patients with AD show no response or minimal response to antipsychotics for symptoms of agitation/aggression or psychosis, or they have intolerable side effects on these medications.
- Conditions
- Alzheimer's Disease, Psychosis, Agitation
- Trial name
- NCT02129348
- Testing
- Lithium
- Where
- 4 sites in United States
- Volunteers
- 77 people
- Sponsor
- New York State Psychiatric Institute
Psychosis
Tolerance and Effect of Antipsychotics in Children and Adolescents With Psychosis
The benefits and harms of antipsychotics are relatively well studied in adults. However, there is a lack of scientifically valid studies regarding the benefits and harms of antipsychotics in children and adolescents with…
- Trial name
- TEA (NCT01119014)
- Testing
- Aripiprazole, Quetiapine
- Where
- 9 sites in Denmark
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Anne Katrine Pagsberg
Schizophrenia, Treatment-resistant Schizophrenia
Multidisciplinary Design to Optimize Schizophrenia Treatment Based on Multi-omics Data and Systems Biology Analysis
SchizOMICS is a Phase IV, multicenter, dose-flexible, open-label, randomized controlled clinical trial to evaluate the efficacy and safety of aripiprazole versus paliperidone using multi-omics data in patients with a first…
- Conditions
- Schizophrenia, Treatment-resistant Schizophrenia, Side Effect, Lipid Metabolism Disorders
- Trial name
- SchizOMICS (NCT06060886)
- Testing
- Aripiprazole, Paliperidone
- Volunteers
- 244 people
- Sponsor
- Consorcio Centro de Investigación Biomédica en Red (CIBER)
First Episode Psychosis
Efficacy of Treating First Episode Psychosis With Folic Acid,B12 and B6 in Addition to Antipsychotic Medication
The purpose of this study is to determine whether Vitamin B12,B6 and Folic Acid are effective with antipsychotic medication in the treatment of First Episode Psychosis.The B-complex Vitamins' homocysteine lowering properties may…
- Trial name
- NCT00202280
- Testing
- Folic Acid 5mg, Vitamin B12 0.4mg and B6 50mg
- Where
- Australia
- Volunteers
- 120 people
- Sponsor
- Melbourne Health
Chromosome 22q11.2 Deletion Syndrome
Genetics and Psychopathology in the 22q11 Deletion Syndrome
The purposes of this study are to: 1. study the nature and longitudinal course of psychiatric symptoms in children with the 22q11.2 deletion syndrome and 2. identify genes that contribute to the occurrence of these symptoms.
- Trial name
- NCT00161109
- Where
- 2 sites in United States, Netherlands
- Volunteers
- 175 people, healthy volunteers welcome
- Sponsor
- UMC Utrecht
Schizophrenia and Disorders With Psychotic Features
Specialized Treatment Early in Psychosis (STEP)
The purpose of this study is to understand the effectiveness of a specialized package of phase-specific treatments for individuals in the midst of their first episode of psychosis.
- Trial name
- STEP (NCT00309452)
- Testing
- Cognitive Behavioral Group Therapy, Cognitive remediation, Medications
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Yale University
Schizophrenia, Bipolar Disorder
Indicated Prevention of Psychotic Disorders With Low-dose Lithium
This study investigates the neuroprotective properties of low-dose lithium in young individuals at ultra-high risk of developping a first psychotic episode.
- Conditions
- Schizophrenia, Bipolar Disorder, Psychotic Disorders
- Trial name
- NCT00202306
- Testing
- lithium carbonate
- Where
- Australia
- Volunteers
- 30 people
- Sponsor
- Melbourne Health
Schizophrenia, Schizoaffective Disorder
Neurophysiological Studies in Schizophrenia and Psychiatric Disorders
The overall goal of this project is to identify intermediate phenotypes for psychosis across the schizophrenia and bipolar disorders boundary with implications for future genetic studies.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
- Trial name
- BSNIP (NCT01384604)
- Where
- United States
- Volunteers
- 1,189 people, healthy volunteers welcome
- Sponsor
- University of Texas Southwestern Medical Center
Psychotic Disorders, Schizophrenia
Mindfulness Group-based Intervention for Early Psychosis
Recent research has suggested that mindfulness-based interventions (MBI) for psychosis may be effective in reducing the negative symptoms of schizophrenia (e.g., social withdrawal, lack of motivation) and the distress associated…
- Trial name
- NCT03143907
- Testing
- Mindfulness Ambassador Council for Early Psychosis (MAC-EP)
- Where
- 5 sites in Canada
- Volunteers
- 70 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Engagement, Patient, First Episode Psychosis
Optimizing Engagement in Services for First-Episode Psychosis
This study will compare a 12-session behavioral activation (BA) intervention modified for first-episode psychosis (FEP) to usual community mental health care (i.e., treatment-as-usual; TAU) delivered over 6 months with a sample…
- Trial name
- NCT05310838
- Testing
- Behavioral Activation for First Episode Psychosis, Treatment As Usual
- Where
- 2 sites in United States
- Volunteers
- 28 people
- Sponsor
- California State University, San Bernardino
Schizophrenia, Psychotic Disorder NOS
The Effect of N-Acetyl Cysteine on Cortical Erosion in Early Stage Schizophrenia
The primary objective of this study is to determine if NAC, added to existing antipsychotic treatment, is superior to placebo for cortical erosion in patients with early stage psychosis.
- Conditions
- Schizophrenia, Psychotic Disorder NOS, Schizoaffective Disorder, Schizophreniform
- Trial name
- Breier-Stanley (NCT01339858)
- Testing
- N-Acetyl Cysteine, sugar pill
- Where
- 2 sites in United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Indiana University
Psychosis
Adaptation of Cognitive Enhancement Therapy for Persons at Clinical High Risk for Psychosis
The purpose of this study is to test the feasibility of a modification of CET (Cognitive Enhancement Therapy) to address symptomatic and functional difficulties associated with Clinical High Risk for Psychosis (CHR).
- Trial name
- CLUES (NCT02459210)
- Testing
- CLUES, therapy and computer games
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- Beth Israel Deaconess Medical Center
Obesity, Vitamin D Deficiency
Vitamin D Supplementation in Psychiatric Illnesses
Children and adolescents with psychiatric illnesses who are treated with medications called second generation antipsychotic agents (SGA) often gain excessive weight during their treatment with these medications.
- Conditions
- Obesity, Vitamin D Deficiency, Psychosis, Schizophrenia
- Trial name
- VDSS (NCT01004354)
- Testing
- Ergocalciferols
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Massachusetts, Worcester
Psychosis, Alcohol Use Disorder
Effects of Action-Based Cognitive Remediation on Substance Misuse in Early Phase Psychosis
Psychotic disorders impact 4.6 people per 1000 globally, with approximately 1.5 million Canadians affected. The age of onset for psychotic disorders often begin during the critical years of youth and early adulthood, resulting in…
- Conditions
- Psychosis, Alcohol Use Disorder, Cannabis Use Disorder
- Trial name
- NCT07056894
- Testing
- Action-Based Cognitive Remediation
- Where
- 2 sites in Canada
- Volunteers
- 50 people
- Sponsor
- Nova Scotia Health Authority
Psychosis, Mother-Child Relations
Pilot Study to Evaluate the Effectiveness of Online Familiar Metacognitive Training (MCTf)
The objective of this study is to adapt and evaluate the efficacy of Familiar Metacognitive Training (MCTf) in mothers and adolescent children in a group context with the main purpose of improving family relationships, cognitive…
- Trial name
- MCTf (NCT05358457)
- Testing
- Familiar Metacognitive Training
- Volunteers
- 48 people
- Sponsor
- Fundació Sant Joan de Déu
Artificial Intelligence, Septic Shock
Artificial Intelligence for Sepsis Prediction in ICU
The development of sepsis prediction model in line with Chinese population, and extended to clinical, assist clinicians for early identification, early intervention, has a good application prospect.
- Conditions
- Artificial Intelligence, Septic Shock, Intensive Care Unit Psychosis
- Trial name
- AICUSepsis (NCT04913181)
- Testing
- Artificial intelligence sepsis prediction model
- Volunteers
- 2,000 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Clinical High Risk, Psychosis
AMP SCZ® Observational Study: PREDICT-DPACC
The Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ) is a large international collaboration to develop algorithms using a set of clinical and cognitive assessments, multi-modal biomarkers, and clinical endpoints that…
- Conditions
- Clinical High Risk, Psychosis, Remission, Conversion
- Trial name
- AMP SCZ (NCT05905003)
- Where
- 42 sites in United States, Australia and 12 more
- Volunteers
- 2,617 people, healthy volunteers welcome
- Sponsor
- Brigham and Women's Hospital
First Episode Psychosis, Schizophrenia
OnTrackNY With the Option of Social Network Meetings
Early intervention programs for psychosis help improve short-term treatment and recovery outcomes for individuals experiencing psychosis.
- Trial name
- NCT03464162
- Testing
- Social Network Meetings
- Where
- United States
- Sponsor
- Lisa Dixon